US Stock MarketDetailed Quotes

TCRT Alaunos Therapeutics

Watchlist
  • 1.9000
  • -0.1800-8.65%
Close Dec 13 16:00 ET
  • 2.0150
  • +0.1150+6.05%
Post 19:26 ET
3.04MMarket Cap-0.26P/E (TTM)

About Alaunos Therapeutics Company

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Company Profile

SymbolTCRT
Company NameAlaunos Therapeutics
Listing DateSep 22, 2006
Founded2003
CEOMr. Dale Curtis Hogue, Jr
MarketNASDAQ
Employees1
Fiscal Year Ends12-31
Address2617 Bissonnet Saint,Suite 225
CityHouston
ProvinceTexas
CountryUnited States of America
Zip Code77005
Phone1-346-355-4099

Company Executives

  • Name
  • Position
  • Salary
  • Dale Curtis Hogue, Jr
  • Director and Interim Chief Executive Officer
  • 11.09K
  • Ferdinand Groenewald
  • Vice President, Finance
  • --
  • Holger Weis
  • Chairman of the Board
  • 900.26K
  • Robert W. Postma
  • Independent Director
  • 104.26K
  • Jaime Vieser
  • Independent Director
  • 103.26K
  • Dr. Robert J Hofmeister, PhD
  • Independent Director
  • 84.01K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.